Hodgkin’s Lymphoma – Epidemiology – Epidemiology – Hodgkin’s Lymphoma – Mature Markets

Clarivate Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of HL for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s HL forecast will answer the following questions:

• Of all people diagnosed with HL, how many in each of the major mature pharmaceutical markets are eligible for first line of treatment?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HL over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts seven HL populations, as follows:

• Diagnosed incident cases of HL.
• Diagnosed incident cases of classical Hodgkin’s lymphoma (CHL).
• Diagnosed incident cases of nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL).
• Diagnosed prevalent cases of CHL.
• Diagnosed prevalent cases of NLPHL.
• Drug-treatable prevalent cases of CHL.
• Drug-treatable prevalent cases of NLPHL.

… and more (details available on request).

Note: Coverage may vary by country.